Table 2.

HCV Genotype 1 and 3 Patient Populations From Daclatasvir Clinical Trials⁸

Trial	Population	Study Arms and Duration (Number of Patients Treated)
ALLY-3	Genotype 3, treatment-näive and treatment-experienced, with or without cirrhosis	Daclatasvir and sofosbuvir for 12 weeks (N = 152)
ALLY-2	Genotypes 1 and 3, treatment-näive and treatment-experienced, with or without cirrhosis, with HCV/HIV-1 coinfection	Daclatasvir and sofosbuvir for 12 weeks (N = 137)
ALLY-1	Genotypes 1 and 3, treatment-näive or treatment-experienced, with or without cirrhosis, including decompensated cirrhosis and post-transplant	Daclatasvir and sofosbuvir plus ribavirin for 12 weeks (N = 103)

HCV = hepatitis C virus; HIV = human immunodeficiency virus